Shopping Cart
- Remove All
- Your shopping cart is currently empty
TT-OAD2 is a non-peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor (EC50: 5 nM), with potential for diabetes treatment.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 mg | Inquiry | Backorder | |
500 mg | Inquiry | Backorder |
Description | TT-OAD2 is a non-peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor (EC50: 5 nM), with potential for diabetes treatment. |
Targets&IC50 | GLP1 receptor:(EC50)5 nM |
In vitro | In HEK293A cells, TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner [1]. |
In vivo | In male human GLP-1 receptor knock-in and knockout mice, TT-OAD2 (3 mg/kg; intravenous injection)treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice[1]. |
Molecular Weight | 929.75 |
Formula | C50H49Cl4N3O6 |
Cas No. | 2382719-60-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.